212 related articles for article (PubMed ID: 26728985)
41. The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients.
Chen S; Ling Z; Kiuchi MG; Yin Y; Krucoff MW
Europace; 2013 Jul; 15(7):992-1001. PubMed ID: 23419662
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system.
Bertoldi EG; Rohde LE; Zimerman LI; Pimentel M; Polanczyk CA
Int J Cardiol; 2013 Mar; 163(3):309-315. PubMed ID: 21704396
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of implantable cardioverter defibrillators and cardiac resynchronization therapy in heart failure.
Freeman JV; Masoudi FA
Heart Fail Clin; 2013 Jan; 9(1):59-77. PubMed ID: 23168318
[TBL] [Abstract][Full Text] [Related]
44. Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology.
Banz K;
Value Health; 2005; 8(2):128-39. PubMed ID: 15804321
[TBL] [Abstract][Full Text] [Related]
45. National Trends in the Use of Cardiac Resynchronization Therapy With or Without Implantable Cardioverter-Defibrillator.
Lindvall C; Chatterjee NA; Chang Y; Chernack B; Jackson VA; Singh JP; Metlay JP
Circulation; 2016 Jan; 133(3):273-81. PubMed ID: 26635400
[TBL] [Abstract][Full Text] [Related]
46. PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy.
Kutyifa V; Stockburger M; Daubert JP; Holmqvist F; Olshansky B; Schuger C; Klein H; Goldenberg I; Brenyo A; McNitt S; Merkely B; Zareba W; Moss AJ
Circ Arrhythm Electrophysiol; 2014 Aug; 7(4):645-51. PubMed ID: 24963007
[TBL] [Abstract][Full Text] [Related]
47. A review of factors contributing to health related quality of life achieved with cardiac resynchronization therapy for heart failure.
Van Hemel NM
Minerva Cardioangiol; 2007 Dec; 55(6):783-802. PubMed ID: 18091646
[TBL] [Abstract][Full Text] [Related]
48. Selection and outcome of implantable cardioverter-defibrillator patients with and without cardiac resynchronization therapy: Comparison of 4384 patients from the German Device Registry to randomized controlled trials.
Köbe J; Willy K; Senges J; Hochadel M; Kleemann T; Spitzer SG; Andresen D; Jehle J; Steinbeck G; Szendey I; Butter C; Brachmann J; Hoffmann E; Eckardt L
J Cardiovasc Electrophysiol; 2022 Mar; 33(3):483-492. PubMed ID: 35028995
[TBL] [Abstract][Full Text] [Related]
49. Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
Ruwald MH; Abu-Zeitone A; Jons C; Ruwald AC; McNitt S; Kutyifa V; Zareba W; Moss AJ
J Am Coll Cardiol; 2013 Oct; 62(15):1343-50. PubMed ID: 23770172
[TBL] [Abstract][Full Text] [Related]
50. Morbidity and mortality with cardiac resynchronization therapy with pacing vs. with defibrillation in octogenarian patients in a real-world setting.
Laish-Farkash A; Bruoha S; Katz A; Goldenberg I; Suleiman M; Michowitz Y; Shlomo N; Einhorn-Cohen M; Khalameizer V
Europace; 2017 Aug; 19(8):1357-1363. PubMed ID: 27733457
[TBL] [Abstract][Full Text] [Related]
51. Implantable cardioverter-defibrillator use in elderly patients receiving cardiac resynchronization: A meta-analysis.
AlTurki A; Proietti R; Alturki H; Essebag V; Huynh T
Hellenic J Cardiol; 2019; 60(5):276-281. PubMed ID: 29292244
[TBL] [Abstract][Full Text] [Related]
52. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial.
Sapp JL; Parkash R; Wells GA; Yetisir E; Gardner MJ; Healey JS; Thibault B; Sterns LD; Birnie D; Nery PB; Sivakumaran S; Essebag V; Dorian P; Tang AS
Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28292754
[TBL] [Abstract][Full Text] [Related]
53. Biventricular pacemaker and defibrillator implantation in patients with chronic heart failure in China.
Huang D; Hua W; Fang Q; Yan J; Su Y; Liu B; Xu Y; Peng Y;
ESC Heart Fail; 2021 Feb; 8(1):546-554. PubMed ID: 33169538
[TBL] [Abstract][Full Text] [Related]
54. Cost-utility analysis of an implantable cardioverterdefibrillator for the treatment of patients with ischemic or non-ischemic New York Heart Association class II or III heart failure in Colombia.
Atehortúa S; Senior JM; Castro P; Ceballos M; Saldarriaga C; Giraldo N; Mora G
Biomedica; 2019 Sep; 39(3):502-512. PubMed ID: 31584764
[TBL] [Abstract][Full Text] [Related]
55. Upgrade from implantable cardioverter-defibrillator vs. de novo implantation of cardiac resynchronization therapy: long-term outcomes.
Jędrzejczyk-Patej E; Mazurek M; Kotalczyk A; Kowalska W; Konieczny-Kozielska A; Kozielski J; Podolecki T; Szulik M; Sokal A; Kowalski O; Kalarus Z; Średniawa B; Lenarczyk R
Europace; 2021 Jan; 23(1):113-122. PubMed ID: 33257952
[TBL] [Abstract][Full Text] [Related]
56. Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.
Marzec LN; Peterson PN; Bao H; Curtis JP; Masoudi FA; Varosy PD; Bradley SM
JAMA Cardiol; 2017 May; 2(5):561-565. PubMed ID: 28122073
[TBL] [Abstract][Full Text] [Related]
57. Economic implications and cost-effectiveness of implantable cardioverter defibrillator and cardiac resynchronization therapy.
Bernard ML; Gold MR
Heart Fail Clin; 2011 Apr; 7(2):241-50, ix. PubMed ID: 21439502
[TBL] [Abstract][Full Text] [Related]
58. Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis.
Chen S; Yin Y; Krucoff MW
Europace; 2012 Nov; 14(11):1602-7. PubMed ID: 23104857
[TBL] [Abstract][Full Text] [Related]
59. Cardiac resynchronization therapy in combination with implantable cardioverter-defibrillator.
Daubert JC; Leclercq C; Mabo P
Europace; 2009 Nov; 11 Suppl 5():v87-92. PubMed ID: 19861397
[TBL] [Abstract][Full Text] [Related]
60. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
